CNS Pharmaceuticals, Inc. announced that it has entered into Securities Purchase Agreements with institutional investors to issue unregistered warrants to purchase up to an aggregate of 568,000 shares of common stock on June 26, 2024. Subject to certain ownership limitations, each of the Common Warrants is immediately exercisable, will have an exercise price of $2.32 per share, and expire five years from the date of issuance. The common warrants to be issued in the Private Placement and the shares issuable upon exercise of the common warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended and Regulation D promulgated thereunder.

The closing of the private placement is expected to occur on June 27, 2024.